Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 8/20 | 0.33 |
| ▸ | MAT2A | P31153 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12613505 | 0.93 | TRPV3 (0.35) | PTGESMAT2AHDAC1HDAC6LRRK2 | |
| SCHEMBL12613543 | 0.90 | ADORA2A (0.35) | HDAC1HDAC6LRRK2BRS3SYK | |
| SCHEMBL1794686 | 0.88 | DGAT1 (0.37) | HDAC1HDAC6LRRK2SYKAURKB | |
| SCHEMBL1790702 | 0.87 | LRRK2 (0.34) | HDAC1HDAC6LRRK2BRS3SYK | |
| SCHEMBL1792547 | 0.87 | DGAT1 (0.34) | HDAC1HDAC6LRRK2SYKAURKB | |
| SCHEMBL5116589 | 0.85 | KDM4E (0.38) | MAPK10 | |
| SCHEMBL12613172 | 0.84 | MAT2A (0.33) | MAT2ALRRK2SYK | |
| SCHEMBL1792727 | 0.83 | DGAT1 (0.35) | HDAC1HDAC6LRRK2SYK | |
| SCHEMBL12613662 | 0.83 | LRRK2 (0.33) | HDAC1HDAC6LRRK2BRS3SYK | |
| SCHEMBL1790637 | 0.82 | PTGS2 (0.41) | PTGESLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536187-B2 | 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110123493-A1 | 2,4,6-TRISUBSTITUTED PYRIDO(3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS | PNPO, CYP2S1, DPYD | PTGES 414/4885MAT2A 544/4885HDAC1 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.